In GBM and non-small cell lung cancer (NSCLC), the inhibition of EAF2 by EZH2 leads to a reduction in pVHL, thus augmenting the protein level and activity of HIF-1α by preventing the ubiquitin-dependent degradation process. The gene discussed is EZH2; the disease is glioblastoma.